In vitro activities of five quinolones against Chlamydia pneumoniae | Zendy

M R Hammerschlag | Zendy; Charles Hyman | Zendy; P M Roblin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activities of five quinolones against Chlamydia pneumoniae

Author(s) -

M R Hammerschlag,

Charles Hyman,

P M Roblin

Publication year - 1992

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.36.3.682

Subject(s) - fleroxacin , sparfloxacin , ofloxacin , ciprofloxacin , pefloxacin , microbiology and biotechnology , quinolone , chlamydia , antibacterial agent , chlamydophila pneumoniae , lomefloxacin , chlamydiaceae , in vitro , antibiotics , chemistry , biology , immunology , biochemistry

The in vitro susceptibilities of 10 strains of Chlamydia pneumoniae were determined for five quinolones, including ciprofloxacin, ofloxacin, fleroxacin, temafloxacin, and sparfloxacin. Sparfloxacin was the most active compound tested, followed by ofloxacin and temafloxacin. Ciprofloxacin and fleroxacin were the least active. The use of HEp-2 cells for testing C. pneumoniae resulted in larger inclusions but essentially the same endpoints as were seen with use of HeLa 229 cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research